We are pleased to announce that we have received a positive evaluation and recommendation for funding in the Medical Research Agency Competition for the implementation of research in the area of drug safety, innovative therapies and drugs of the future (2024/ABM/05/KPO).
This prestigious award will enable us to further develop innovative targeted therapies in oncology. With the funding, we will continue to develop innovative dextran conjugates that have the potential to be used in targeted anticancer therapy. Our goal is to develop novel therapeutic solutions that precisely deliver drugs to cancer cells, increasing the effectiveness of therapy and minimizing side effects.
This achievement confirms NanoGroup S.A.’s potential to create breakthroughs in the field of oncology. We are confident that with the commitment of our team and the support of the Medical Research Agency, we will contribute to significant advances in cancer treatment.
We thank our partners and stakeholders for their trust and support. Together we are building a better future in medicine.
More information on the results of the competition is available on the Medical Research Agency website: